Boc- ß-HoIle-OHCAS# 218608-82-3 |
2D Structure
- Cisplatin
Catalog No.:BCN1552
CAS No.:14283-03-5
- Z-VAD-FMK
Catalog No.:BCC1126
CAS No.:187389-52-2
- Z-WEHD-FMK
Catalog No.:BCC1139
CAS No.:210345-00-9
- Z-LEHD-FMK
Catalog No.:BCC5117
CAS No.:210345-04-3
- AZ 10417808
Catalog No.:BCC2356
CAS No.:331645-84-2
- Apoptosis Activator 2
Catalog No.:BCC2099
CAS No.:79183-19-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 218608-82-3 | SDF | Download SDF |
PubChem ID | 2761522 | Appearance | Powder |
Formula | C12H23NO4 | M.Wt | 245.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (3R,4R)-4-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid | ||
SMILES | CCC(C)C(CC(=O)O)NC(=O)OC(C)(C)C | ||
Standard InChIKey | CMRZYYUYDQRCEO-RKDXNWHRSA-N | ||
Standard InChI | InChI=1S/C12H23NO4/c1-6-8(2)9(7-10(14)15)13-11(16)17-12(3,4)5/h8-9H,6-7H2,1-5H3,(H,13,16)(H,14,15)/t8-,9-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Boc- ß-HoIle-OH Dilution Calculator
Boc- ß-HoIle-OH Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.0766 mL | 20.3832 mL | 40.7664 mL | 81.5328 mL | 101.916 mL |
5 mM | 0.8153 mL | 4.0766 mL | 8.1533 mL | 16.3066 mL | 20.3832 mL |
10 mM | 0.4077 mL | 2.0383 mL | 4.0766 mL | 8.1533 mL | 10.1916 mL |
50 mM | 0.0815 mL | 0.4077 mL | 0.8153 mL | 1.6307 mL | 2.0383 mL |
100 mM | 0.0408 mL | 0.2038 mL | 0.4077 mL | 0.8153 mL | 1.0192 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Boc- ß-HoIle-OH
- Bardoxolone methyl
Catalog No.:BCC1400
CAS No.:218600-53-4
- Bardoxolone
Catalog No.:BCC1399
CAS No.:218600-44-3
- Falcarinol
Catalog No.:BCN3938
CAS No.:21852-80-2
- Octahydroisoindole
Catalog No.:BCN2275
CAS No.:21850-12-4
- BDNF (human)
Catalog No.:BCC5944
CAS No.:218441-99-7
- Macrocarpal K
Catalog No.:BCN4934
CAS No.:218290-59-6
- Nifedipine
Catalog No.:BCC4808
CAS No.:21829-25-4
- Vindoline
Catalog No.:BCN4933
CAS No.:2182-14-1
- SRPIN340
Catalog No.:BCC4849
CAS No.:218156-96-8
- SC 26196
Catalog No.:BCC7880
CAS No.:218136-59-5
- Isopteleine
Catalog No.:BCN7067
CAS No.:2181-84-2
- Potassium Canrenoate
Catalog No.:BCC3844
CAS No.:2181-04-6
- 12-Hydroxyisodrimenin
Catalog No.:BCN4935
CAS No.:218780-16-6
- Boc-Arg(NO2)-OH
Catalog No.:BCC3065
CAS No.:2188-18-3
- Lycorine chloride
Catalog No.:BCN1220
CAS No.:2188-68-3
- Horminone
Catalog No.:BCN4936
CAS No.:21887-01-4
- Boc-Orn-OH
Catalog No.:BCC3427
CAS No.:21887-64-9
- 1-Phenyloctane
Catalog No.:BCN2227
CAS No.:2189-60-8
- Taraxeryl acetate
Catalog No.:BCN4937
CAS No.:2189-80-2
- Ciwujiatone
Catalog No.:BCN7598
CAS No.:218901-26-9
- Euphorbia factor L2
Catalog No.:BCN3783
CAS No.:218916-51-9
- 5,15-Diacetyl-3-benzoyllathyrol
Catalog No.:BCN1196
CAS No.:218916-52-0
- Euphorbia factor L8
Catalog No.:BCN3785
CAS No.:218916-53-1
- KNK437
Catalog No.:BCC6399
CAS No.:218924-25-5
Efficient synthesis of (S)-N-Boc-3-hydroxypiperidine using an (R)-specific carbonyl reductase from Candida parapsilosis.[Pubmed:28243985]
World J Microbiol Biotechnol. 2017 Mar;33(3):61.
(S)-N-Boc-3-hydroxypiperidine (S-NBHP) is a critical chiral intermediate in the synthesis of pharmaceuticals, including ibrutinib, the active pharmaceutical ingredient of the new drug Imbruvica approved for the treatment of lymphoma. An (R)-specific carbonyl reductase from Candida parapsilosis (CprCR, also known as R-specific alcohol dehydrogenase) that catalyzes asymmetric reduction to produce (S)-N-Boc-3-hydroxypiperidine (S-NBHP) was identified for the first time. When co-expressed with a glucose dehydrogenase from Bacillus megaterium in Escherichia coli Rosetta (DE3), recombinant crude enzyme exhibited an activity of 9 U/mg with N-Boc-3-piperidone as the substrate and 12 U/mg with glucose as the substrate. The biocatalysis of N-Boc-3-piperidone to S-NBHP using recombinant whole-cell biocatalysts was processed in a water/butyl acetate system as well as an aqueous monophasic system without extra NAD(+)/NADH. This process showed great commercial potential, with a 100 g/l substrate concentration and a whole cells loading (w/v) of 10%, with the conversion of 97.8% and an e.e. of 99.8% in an aqueous monophasic system.
Tuning the Molar Composition of "Charge-Shifting" Cationic Copolymers Based on 2-(N,N-Dimethylamino)Ethyl Acrylate and 2-(tert-Boc-Amino)Ethyl Acrylate.[Pubmed:28045212]
Macromol Rapid Commun. 2017 Mar;38(5).
Copolymers of 2-(N,N-dimethylamino)ethyl acrylate (DMAEA) and 2-(tert-Boc-amino)ethyl acrylate (tBocAEA) are synthesized by reversible addition-fragmentation chain transfer polymerization in a controlled manner with defined molar masses and narrow molar masses distributions (Eth = 1.17). Molar compositions of the P(DMAEA-co-tBocAEA) copolymers are assessed by means of (1) H NMR. A complete screening in molar composition is studied from 0% of DMAEA to 100% of DMAEA. Reactivity ratios of both comonomers are determined by the extended Kelen-Tudos method (r DMAEA = 0.81 and rtBocAEA = 0.99).
Rhodium(III)-Catalyzed Ortho-Alkenylation of Anilines Directed by a Removable Boc-Protecting Group.[Pubmed:28322570]
Org Lett. 2017 Apr 7;19(7):1800-1803.
The rhodium(III)-catalyzed ortho-alkenylation of N-Boc-anilines with alkenes such as acrylate ester and styrene proceeds smoothly through C-H bond cleavage. Obtained o-alkenylanilines can be readily transformed to nitrogen-containing fused heteroaromatic compounds including indoles and quinolines.
Effects on Energy Metabolism of Two Guanidine Molecules, (Boc)2 -Creatine and Metformin.[Pubmed:28128472]
J Cell Biochem. 2017 Sep;118(9):2700-2711.
Several enzymes are involved in the energy production, becoming a possible target for new anti-cancer drugs. In this paper, we used biochemical and in silico studies to evaluate the effects of two guanidine molecules, (Boc)2 -creatine and metformin, on creatine kinase, an enzyme involved in the regulation of intracellular energy levels. Our results show that both drugs inhibit creatine kinase activity; however, (Boc)2 -creatine displays a competitive inhibition, while metformin acts with a non-competitive mechanism. Moreover, (Boc)2 -creatine is able to inhibit the activity of hexokinase with a non-competitive mechanism. Considering that creatine kinase and hexokinase are involved in energy metabolism, we evaluated the effects of (Boc)2 -creatine and metformin on the ATP/AMP ratio and on cellular proliferation in healthy fibroblasts, human breast cancer cells (MDA-MB-468), a human neuroblastoma cell line (SH-SY5Y), a human Hodgkin lymphoma cell line (KMH2). We found that healthy fibroblasts were only partially affected by (Boc)2 -creatine, while both ATP/AMP ratio and viability of the three cancer cell lines were significantly decreased. By inhibiting both creatine kinase and hexokinase, (Boc)2 -creatine appears as a promising new agent in anticancer treatment. Further research is needed to understand what types of cancer cells are most suitable to treatment by this new compound. J. Cell. Biochem. 118: 2700-2711, 2017. (c) 2017 Wiley Periodicals, Inc.